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Recessive dystrophic epidermolysis bullosa (RDEB) is an autosomal recessive disorder characterized by the loss
of collagen type VII, an intrinsic component of the anchoring ﬁbrils, which attach the epidermis to the dermis. Of
the genetic blistering disorders, RDEB has the highest rate of morbidity and mortality, with morbidity arising from
fusion of digits in a mitten-glove deformity and growth retardation associated with anemia. The leading cause of
death in RDEB is cutaneous squamous cell carcinoma, which causes death through invasion and metastasis. In
order to better understand the pathogenesis of these rare but aggressive squamous cell carcinoma (SCC), we
analyzed them for mutations in p53 and loss of p16ink4a. Three tumors demonstrated mutations in the p53 tumor
suppressor gene. We also analyzed SCC from patients with RDEB for the presence of p16ink4a hypermethylation,
and found two tumors that have loss of p16ink4a through hypermethylation. This is the ﬁrst description of specific
abnormalities in tumor suppressor genes in RDEB associated SCC, and demonstrates that alterations in both p53
and p16ink4a can contribute to RDEB associated SCC.
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Recessive dystrophic epidermolysis bullosa (RDEB) is a
severe autosomal recessive disorder caused by reduction
or absence of collagen type VII (Kalinke et al, 1994; McG-
rath et al, 1999). Patients with RDEB experience severe
blistering, fusion of digits, growth retardation, and anemia
due to continuous blood loss. The major cause of death,
however, is squamous cell carcinoma (SCC) of the skin
(Reed et al, 1975; Keefe et al, 1988; McGrath et al, 1991).
Patients with RDEB have been noted to have a 70-fold el-
evated risk of development of SCC compared with unaf-
fected patients (Smoller et al, 1990).
We have previously demonstrated that hypermethylation
of p16ink4a is a hallmark of reactive oxygen-induced car-
cinogenesis (Govindarajan et al, 2002). Chronic growth fac-
tor stimulation is known to cause sustained production of
reactive oxygen, and cancers associated with reactive ox-
ygen induced carcinogenesis tend to be highly aggressive
and exhibit p16ink4a hypermethylation (Linardopoulos et al,
1995; Merlo et al, 1995; Arbiser et al, 1998a; Martin et al,
2000). We thus examined SCC samples derived from RDEB
patients, and found that two of eight samples exhibited
p16ink4a hypermethylation, and three tumors exhibited p53
mutations, two of which resemble p53 mutations in alkylat-
ion repair deficient tumors. Our results imply that both the
p53 and p16ink4a pathways are involved in the pathogen-
esis of RDEB-associated SCC.
Results
Mutations in both p53 and hypermethylation of p16ink4a
were observed in a subset of samples (Fig 1, Table I). In two
of the samples, tumors 3 and 6, the same mutation, a TGC
to TAC transition in codon 176 of exon 5, was discovered in
the SCC tumors from both patients, whereas tumor #8
contained an AGG to AAG transition in codon 249 of exon 7.
Tumors 6 and 8 exhibited methylation of p16ink4a.
Discussion
RDEB is a autosomal recessive disorder with extreme mor-
bidity and mortality. The leading cause of mortality in adults
with RDEB is the development of squamous cell carcinoma
(SCC). SCC in RDEB differs from common cutaneous SCC
in that it presents in earlier ages, and is far more likely to
metastasise than common sun-induced cutaneous SCC.
Although direct DNA exposure, leading to thymine dimers is
a well-known causative event in cutaneous SCC (Ziegler
et al, 1993), the mechanism of SCC development in RDEB
patients is less well understood. RDEB-induced SCC arise
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in the background of severe inflammation, similar to other
aggressive cutaneous SCC, such as those arising in sinus
tracts, ulcers (Marjolin’s ulcers), and radiation-induced cu-
taneous SCC.
Lesions were observed in critical areas of p53. Unlike the
lesions observed in ultraviolet induced SCC, these lesions
did not affect the codons usually affected by ultraviolet light
(UV signatures). Although C–T transitions, as usually seen in
ultraviolet light-induced carcinogenesis, were not observed,
all three tumors exhibiting mutations in p53 demonstrated G
to A transitions, which are commonly observed in a subset
of carcinomas of the lung (Wolf et al, 2001). Although this
mutational spectrum could be consistent with UV-induced
damage to the non-transcribed strand, this is also a signa-
ture mutation for oxidative damage to guanine bases in DNA
and suggests the possibility that other forms of mutagen-
esis other than direct ultraviolet-induced DNA damage, are
operative in RDEB-associated SCC (Esteller and Herman,
2004). The p53 mutations identified in RDEB-SCC are as-
sociated with mutations in the DNA binding regions of p53,
and p53 proteins with mutations in these codons have been
found to have defects in DNA binding, but not interac-
tion with other potential tumor suppressors. Thus, these
proteins have dominant negative functions in that they se-
quester other tumor suppressor genes, whereas they
are defective in DNA binding (Dittmer et al, 1993; Marutani
et al, 1999; Olivier et al, 2002).
Although the role of mutant p53 in cutaneous SCC is well
established, the role of p16 hypermethylation is less well
established. In an extensive study of cutaneous squamous
neoplasia, Tyler et al (2003) found p16 hypermethylation
occurring only once in 15 cutaneous squamous cell carci-
noma due to sun exposure, and no p16 hypermthylation in
actinic keratoses. Although our sample of RDEB-associated
SCC is small due to scarcity of lesions, our findings are
informative for the following reasons. First, we saw an in-
creased frequency of p16 hypermethylation in RDEB-asso-
ciated SCC compared with previous data on UV-induced
SCC. Second, we did not observe the UV signature muta-
tion of p53 in our cohort.
Chemopreventive and treatment strategies for RDEB-
associated SCC are urgently needed. Our current and pre-
vious studies suggest that oxidative stress contributes to
the development of a subset of SCC in this population
through induction of p16 hypermethylation (Govindarajan
et al, 2002). A number of chemopreventive agents with
antioxidant properties exist, including retinoids, curcumin,
and tea polyphenols (Arbiser et al, 1998b; Bech-Otschir
et al, 2001; Elmets et al, 2001). Given that b-carotene and
retinol have been associated with an increased incidence of
lung cancer in certain chemopreventive trials, preclinical
studies are needed to assess each potential chemopreven-
tive agent (Omenn et al, 1996). Future studies could involve
animal models, which develop SCC with a mutation spec-
trum more similar to RDEB. An understanding of the mo-
lecular mechanisms that drive neoplastic progression in
RDEB-associated SCC may lead to novel insights into pre-
vention and therapy (Arbiser, 2004).
Materials and Methods
Clinical information The institutional review board of the Emory
University approved all described studies, and the participants
gave their written informed consent. The study was conducted
according to Declaration of Helsinki Principles. The squamous cell
carcinomas were obtained from two patients with RDEB-HS sub-
type. The first patient was a woman who had five separate Mohs’
excisions for SCC on the right arm and scalp, the first at age 20.
She died at age 27 from metastatic SCC. The second patient is a
38 y woman with RDEB-HS, who was noted to have SCC of the
right hand in 1999. She was treated with Mohs’ excision and but it
recurred in 2001, which led to amputation of the right hand in
February 2002. Three mo later, she was noted to have spread of
tumor to her upper arm, which neccessitated further amputation of
the arm, and radiation therapy. She still remains alive and is cur-
rently receiving palliative care.
p53 mutation analysis DNA purified from paraffin embedded tis-
sue was used as a template for p53 mutation analysis. Exons 5–8
of p53 were amplified by PCR using intronic primers determined
from the sequence reported in GenBank Accession No. X54156.
Each exon was amplified separately in a 100 mL PCR reaction
containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM of MgCl2,
0.2 mM each of forward and reverse primers, 0.2 mM of dNTP mix,
4 U of AmpliTaq Gold polymerase, and 2 mL of template DNA. The
cycling conditions consisted of a 10 min 941C denaturing step
followed by 40 cycles of denaturation at 941C for 30 s, annealing at
58–651C for 2 min, and elongation at 721C for 2 min followed by a
final elongation step of 7 min at 721C. Following the primary am-
plification, 2 mL of PCR product were amplified a second time with
intronic nested primers as described by Cripps et al (1994) using
the same conditions as the primary amplification except that the
cycles were reduced to 20 and the annealing and extension times
were reduced to 1 min. The PCR products were visualized on a 1%
agarose gel containing 0.1% ethidium bromide to assure amplifi-
cation of products of the correct size.
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Figure 1
Promoter methylation of p16ink4a in SCC samples. The number
above the lanes represents the tumor number. Specimens 1–3 revealed
no p16ink4 hypermethylation, thus were not included. Lanes labelled U
represent p16 unmethylated-specific primer; lanes labeled M, methyl-
ated-specific primer.
Table I. p53 mutation status and p16 promoter methylation
status of RDEB-associated squamous cell carcinoma. Methyl-
ation of the p16 promoter is indicated by a ‘‘þ ’’
Sample
p53
status
p16
MSP Histologic characteristics
1 WT  Invasive, perineural invasion
2 WT  Well differentiated
3 Exon 5  Invasive
4 WT  Invasive
5 WT  Invasive
6 Exon 5 þ Poorly differentiated with large nucleoli
7 WT  Invasive
8 Exon 7 þ Invasive, perineural invasion
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Following the secondary amplification, PCR products were
analyzed by single-strand conformation polymorphism (SSCP)
analysis using the GenePhor Electrophoresis Unit (Amersham Bio
sciences, Piscataway, New Jersey). Bands were visualized with the
Plus One DNA Silver Staining Kit (Amersham Biosciences) as de-
scribed in the manufacturer’s protocol. Shifted bands indicative of
single base pair mutations were cut from the gel, reamplified with
the nested primers, and PCR products were gel purified. These
PCR samples were further analyzed by direct sequencing in both
the forward and reverse directions by the Wake Forest University
Core Sequencing Facility to identify the type of mutation present in
the sample. Sequences were compared to the GenBank sequence
(Accession No. X54156). All identified mutations were confirmed by
repeating the PCR-SSCP process to ensure that they were not due
to Taq polymerase-induced errors.
Bisulﬁte modiﬁcation of DNA for MSP DNA samples, negative (Hu-
man placental DNA; Sigma, St. Louis, Missouri) and positive
(CpGenome universal methylated human DNA; Intergen, New York,
New York) controls were subjected to bisulfite modification prior to
MSP using CpGenome DNA modification Kit (Intergen).
PCR ampliﬁcation and primers Amplification of the promoter re-
gion of the p16 gene was carried out in a Touchgene Gradient
Thermal Cycler (Techne, Princeton, New Jersey) in a 50-mL PCR
reaction mixture containing 2 mL of bisulfite-treated genomic DNA,
dNTPs (each at 200 mM), primers (50 pmol each per reaction), 2.5
mM MgCl2, and 1.25 U Hotstar Taq (Qiagen, Valencia, California) in
1  PCR buffer. All reagents were supplied with the Qiagen Hotstar
Taq Kit (Qiagen). The only exception was the dNTP mix (Roche
Molecular Biochemicals, Indianapolis, Indiana).
Primers for p16 gene are designed as follows: 50-TTATTA-
GAGGGTGGGGTGGATTGT-30 (sense) and 50-CAACCCCAAACC
ACAACCATAA-30 (antisense) for the unmethylated reactions; 50-
TTATTAGAGGGTGGGGCGGATCGC-30 (sense) and 50-GACCCCC-
GAACCGCGACCGTAA-30 (antisense) for the methylated reactions
as described previously (Sanchez-Cespedes et al, 2000; Rosas
et al, 2001). Both primers are purchased from Operon Technologies
(Alameda, California). The PCR conditions were as follows: initial
denaturation and hot start at 951C for 15 min, then 40 cycles con-
sisting of 30 s at 951C, 30 s at 601C (unmethylated reactions) or
651C (methylated reactions) and 1 min at 721C followed by a final
5-min extension at 721C. Positive and negative control DNA sam-
ples and controls without DNA were used for each set of PCR
(Cripps et al, 1994).
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